PremiumThe FlyProMIS highlights preclincal data on platform-derived antibody, vaccines ProMIS Neurosciences to present preclinical data on vaccines at AAN meeting Is PMN a Buy, Before Earnings? PremiumCompany AnnouncementsProMIS Neurosciences Highlights Neurodegenerative Disease Focus ProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26 ProMIS Neurosciences Launches Phase 1b Trial for Alzheimer’s PremiumThe FlyProMIS Neurosciences to showcase PMN310 at ICBN ProMIS Neurosciences files to sell 56.51M common shares for holders ProMIS Neurosciences reports Q2 EPS (13c) vs (27c) last year 
